Abstract-For
S
troke is a leading cause of adult disability and death worldwide. 1 A key aim to management of patients with ischemic stroke and transient ischemic attacks (TIA) is to reduce the high early risk of recurrent stroke 2 and long-term risk of all serious nonfatal and fatal vascular events. 3 Randomized trials have established antiplatelet therapy as a cornerstone for secondary stroke prevention. 4 The Antiplatelet and Antithrombotic Trialists' collaborations 4 reported that random assignment to any antiplatelet therapy compared with control (placebo or no antiplatelet therapy) was associated with an 11% reduction in odds of stroke, myocardial infarction, or death attributable to vascular causes (serious vascular events) among patients with acute ischemic stroke (nϭ40 821) and a 22% reduction for long-term secondary prevention in patients with prior ischemic stroke or TIA (nϭ23 020). 4 Aspirin was the first antiplatelet agent to be used for secondary stroke prevention and remains the most commonly prescribed agent. However, over the past 2 decades, a number of other antiplatelet agents and combinations of antiplatelet drugs have been evaluated in an attempt to improve on the effectiveness and safety of aspirin. 5 In this article, we review the evidence from randomized trials for the effectiveness and safety of established and emerging antiplatelet therapies for secondary prevention of serious vascular events among patients with ischemic stroke and TIA and provide recommendations for their use.
Methods

Search Strategy
We identified randomized trials and meta-analyses of randomized trials that compared antiplatelet therapy with placebo or no antiplatelet therapy or that compared different antiplatelet therapies with each other by searching electronic databases (PUBMED, Cochrane Database of Clinical Trials) between 1966 and April 2007 using the following MeSH terms: stroke, antiplatelet therapy, aspirin, clopidogrel, ticlopidine, dipyridamole, novel antiplatelet therapy, glycoprotein IIb/IIIa inhibitor, bleeding, intracranial hemorrhage, clinical trial, and methodology. We examined the "relevant articles" links in PUBMED and used the Science Citation index to identify additional studies. One investigator (M.O.) conducted the search and the selection of articles for inclusion was by consensus of all authors. Only English language articles were included. For the purpose of this review we considered trials that recruited patients within 14 days of symptom onset as acute ischemic stroke trials. All other trials were considered to be chronic ischemic stroke trials.
Acute Ischemic Stroke
There have been 11 trials comparing antiplatelet therapy to control involving 42 648 patients with acute ischemic stroke. Four of these trials compared aspirin to control, 7-10 1 compared aspirin plus dipyridamole to control, 11 3 trials compared ticlopidine to control, 12-14 1 trial compared thromboxane synthase inhibitor to control, 15 and 2 trials compared abciximab to control. 16, 17 Two trials (International Stroke Trial and Chinese Acute Stroke Trial) evaluating aspirin 160 to 300 mg once daily started within 48 hours of onset. The maximum duration of follow-up was 6 months (Table 1) .
Aspirin Versus Placebo or Untreated Control
Trials
Four trials have compared aspirin to control in a total of 41 291 patients with acute ischemic stroke. [7] [8] [9] [10] More than 98% of data came from 2 trials (IST and CAST), which followed patients for a total of 1 and 6 months. 7, 8 Efficacy Meta-analysis 18 of the data from 3 trials 7, 8, 10 indicate that random assignment to aspirin 160 to 300 mg daily, started within 48 hours of onset of symptoms of ischemic stroke, and continued for about 2 to 4 weeks, compared with control, was associated with a 23% reduction in odds of recurrent ischemic stroke (3 18 Subgroup-specific analyses found no significant heterogeneity of the benefits of early aspirin over 2 to 4 weeks among 28 subgroups examined, which included the elderly, gender, and ischemic stroke subtypes.
Safety
Against these benefits, random assignment to aspirin was associated with a 22% increase in odds of symptomatic intracranial hemorrhage (0.8% [control] 
Abciximab Versus Aspirin
Trials
Two trials have compared intravenous abciximab (a longacting glycoprotein IIb/IIIa antagonist) to placebo in aspirintreated patients with stroke. 16, 17 Efficacy A phase IIb trial (AbESTT) randomized 400 patients within 5 hours of onset of ischemic stroke to abciximab 0.25 mg/kg intravenous bolus followed by a 12-hour infusion of 0.125 g/kg per minute or placebo. At 3 months, there was no significant difference in death or dependency, defined as a modified Rankin Scale (mRS) of 2 to 6 (60% [placebo] versus 52% [abciximab], OR: 0.71, 95% CI: 0.48 to 1.05). AbESTT-II aimed to randomize 1800 patients within 5.5 hours of ischemic stroke to receive abciximab or placebo (all patients were treated with aspirin), but the trial was terminated early after 808 patients were enrolled because of an excess of bleeding (see below).
Safety
The AbESTT study did not report a significantly increased risk of symptomatic intracranial hemorrhage (1.0% [placebo] versus 3.5% [abciximab], OR: 3.11, 95% CI: 0.8 to 11.6), 16 
Aspirin and Clopidogrel Versus Aspirin
One trial (FASTER), reported in abstract only, compared combination aspirin and clopidogrel (300 mg loading followed by 75 mg/d) to aspirin alone in patients presenting within 24 hours of a minor ischemic stroke or TIA (factorial design with simvastatin 40 mg/d). 20 The pilot study was terminated early after 392 patients were randomized because of slow recruitment, and it reported a nonsignificant reduction in the primary outcome of all-stroke at 90 days in the combination antiplatelet therapy group (ARR 3.8%; Pϭ0.19). 20 Clinical follow-up in individual trials ranged from 10 days to 6 months. Subsequent to this meta-analysis, 24 another clinical trial has been published, 23 comparing the efficacy and safety of early administration, within 48 hours of onset of ischemic stroke, of subcutaneous nadroparin calcium 3800 antifactor Xa IU/0.4 mL twice daily with oral aspirin 160 mg daily for 10 days, followed by aspirin 80 to 300 mg once daily for 6 months, among 603 Asian patients with acute ischemic stroke attributable to large artery occlusive disease.
Antiplatelet Therapy Versus Anticoagulation
Efficacy
The meta-analysis of the 4 earlier RCTs 7, 11, 21, 22 indicates that random allocation to parenteral anticoagulation compared with aspirin was associated with no significant difference in recurrent ischemic stroke (OR 1.09, 95% CI: 0.89 to 1.33), recurrent stroke of any type (OR 1.20, 95% CI: 0.99 to 1.46), pulmonary embolism (OR 0.85, 95% CI 0.55 to 1.32), and death or dependency (62.0% [aspirin] versus 63.4% (heparin), OR 1.07, 95% CI 0.99 to 1.15) but significantly increase the odds of death by 10% (OR 1.10, 95% CI 1.01 to 1.21) at the end of follow-up (Table 2) . 24 The results of the recent trial in Asian patients 23 are consistent with those of the meta-analysis; the proportion of good outcomes (Barthel index Ն85) was 73% among 180 patients assigned LMWH and 69% among 173 patients assigned aspirin (adjusted OR 1.21, 95% CI: 0.74 to 1.99; absolute risk benefit 4%, 95% CI: Ϫ5% to 13%).
Safety
In the meta-analysis, 24 (Table 2) .
Antiplatelet Therapy for Long-Term Secondary Prevention Aspirin Versus Control
Trials A meta-analysis 25 has pooled data from 11 RCTs of longterm aspirin versus control in 9469 patients with previous ischemic stroke or transient ischemic attack. 26 -36 Efficacy Random allocation to long-term aspirin therapy reduced the risk of all serious vascular events by 13% (ie, stroke, myocardial infarction and vascular death; RR: 0.87%, 95% CI: 0.81 to 0.94). 25 The dose of aspirin ranged from 50 mg/d to 1500 mg/d but there was no evidence of heterogeneity in treatment effect by aspirin dose (Table 3) . 
Safety
Dipyridamole Versus Control
Trials One large clinical trial compared dipyridamole to no antiplatelet therapy. 32
Efficacy
In ESPS-2, among patients assigned extended-release dipyridamole 200 mg twice-daily day, the annual relative risk of stroke or death was reduced by 15% compared with placebo 
Safety
Dipyridamole was not associated with an increased risk of any bleeding compared with placebo. However, dipyridamole was associated with an increased frequency of headache, compared with placebo (37.1% dipyridamole versus 32.3% control). Headache was sufficiently severe to lead to discontinuation of study drug in 8.0% of patients in the ESPS-2 trial who were assigned dipyridamole compared with 2.4% discontinuation among those assigned placebo (RR: 3.20; 95% CI: 2.25 to 4.54). 32 Dipyridamole also caused gastrointestinal upset leading to discontinuation of study drug (RR: 1.65; 95% CI: 1.21 to 2.26).
Thienopyridine (Ticlopidine) Versus Control
Trials
One trial compared ticlopidine (250 mg twice-daily) to placebo in 1072 patients with ischemic stroke in the preceding 4 months. 39 Efficacy After a mean follow-up of 24 months, assignment to ticlopidine was associated with a 23% lower relative risk of the composite of stroke, myocardial infarction, or vascular death compared with placebo (14.8% [placebo] versus 11.3%
[ticlopidine]; RR: 0.77, 0.60 to 0.99). 39 Safety Ticlopidine (250 mg twice daily) doubled the risk of major bleeding (0.2% versus 0.4%) and minor bleeding episodes (6.5% versus 3.0%) compared with placebo. Ticlopidine also increased the risk of severe neutropenia (Ͻ450 neutrophils per mm 3 ), occurring in 0.8% of patients in the ticlopidine group compared to 0.2% in placebo group.
Ticlopidine was also associated with an increased risk of thrombotic thrombocytopenic purpura (TTP), affecting about 1 in 5000 patients primarily during the first 3 months of treatment. 40 
Cilostazol Versus Control
Trials
One RCT compared cilostazol (inhibitor of cAMP phosphodiesterase) with placebo in 1095 patients with recent (1 to 6 months ago) ischemic stroke. 41 
Efficacy
Among patients assigned cilostazol 100 mg twice daily day, the annual relative risk of serious vascular events was reduced by 39% compared with placebo (6.8% 
Triflusal Versus Aspirin
Trials Four randomized trials have compared triflusal (a selective cyclooxygenase-2 that is structurally related to aspirin) with aspirin among patients with stroke or TIA (2944 patients; followed for 6 to 47 months). 46 
Oral Glycoprotein IIb/IIIa Inhibitors Versus Aspirin
Trials
The BRAVO trial (nϭ9190) compared lotrafiban, an oral GPIIa/IIa inhibitor, to placebo in aspirin-treated patients with cardiovascular and cerebrovascular disease (41% had a previous history of ischemic stroke), for secondary prevention of major vascular events. 51 
Safety
At interim review, the trial was terminated early because of an excess of vascular deaths in the lotrafiban group. 
Clopidogrel؉Aspirin Versus Aspirin
Dipyridamole and Aspirin Versus Aspirin
Trials
Six clinical trials (nϭ7795) have compared combination dipyridamole and aspirin to aspirin alone 30,32,34,54 -56 ; the 2 most recent and largest trials 32,55 evaluated extended release dipyridamole primarily (85% in ESPRIT used extendedrelease preparation), in contrast to the 4 earlier and smaller trials that evaluated immediate release dipyridamole.
Efficacy
A meta-analysis 55 of all 6 trials revealed that random assignment to the combination of aspirin-DPD was associated with an 18% lower relative risk of serious vascular events compared to aspirin alone (RR 0.82; 95% CI 0.74 to 0.91).
Safety
A meta-analyses of 5 clinical trials that did not include the recently published ESPRIT trial reported no increase in bleeding with the aspirin-DPD regimen compared to aspirin alone. ESPRIT reported an unexpected 42% reduction in the risk of major bleeding with aspirin/E-DPD compared to aspirin (HR 0.58; 95% CI 0.35 to 0.97). 57 58 The risk of bleeding was cumulative over time. The Kaplan-Meier survival curves for survival free of primary intracerebral hemorrhage for each treatment group did not separate until at 3 to 4 months after randomization.
Clopidogrel؉Aspirin Versus Clopidogrel
Antiplatelet Therapy Versus Warfarin Therapy
Trials Seven randomized controlled trials have compared warfarin therapy to antiplatelet therapy for prevention of recurrent major vascular events after transient ischemic attack or minor stroke in patients with noncardioembolic stroke. 59 -65 Efficacy A meta-analysis 66 of 5 of these trials (nϭ4076) did not show superiority of warfarin over antiplatelet therapy. In trials evaluating medium intensity anticoagulation (INR of 2.1 to 3.6), warfarin did not reduce the risk of major vascular events compared to antiplatelet therapy (RR 0.96; 95% CI 0.38 to 2.42).
Since this meta-analysis, a second arm of the ESPRIT trial 61 evaluated whether oral anticoagulation with medium intensity (INR 2.0 to 3.0) is more effective than aspirin (30 to 325 mg/d) in preventing future vascular events in patients with TIA or minor stroke of presumed arterial origin. 61 A total of 1068 patients with recent TIA or minor stroke of presumed arterial origin were randomly assigned within 6 months of onset to open label therapy with either warfarin (nϭ536) or aspirin (nϭ532). After mean follow-up of 4.6 years (SD 2.2), the primary composite of vascular death, nonfatal stroke, nonfatal myocardial infarction, or major bleeding complication occurred in 19% of patients on anticoagulants and 18% patients on aspirin (HR 1.02, 95% CI 0.77 to 1.35).
Interpretation of the Evidence Acute Ischemic Stroke
Aspirin (160 to 300 mg) should be given as soon as possible (and continued as a once daily dose) in patients with suspected acute ischemic stroke, and reduced to lower doses (50 to 150 mg) after 10 to 14 days. In patients who are unable to swallow safely, aspirin may be given per rectum as a suppository or via a nasogastric tube. Anticoagulants offer no net advantages over antiplatelet drugs in acute ischemic stroke. It is usually recommended that patients who have been treated with thrombolytic therapy should probably not be started on aspirin for 24 to 48 hours. This is because nonrandomized comparisons suggest an adverse hemorrhagic interaction between thrombolytic and concomitant antithrombotic therapies, and increased risk of death, in randomized controlled trials of thrombolysis compared to control in acute ischemic stroke. 67, 68 Although many clinicians start clopidogrel or combination dipyridamole/aspirin in preference to aspirin alone during the acute period (particularly in patients already treated with aspirin before onset of stroke symptoms), no large clinical trials have evaluated the effectiveness and safety of this practice.
Long-Term Secondary Prevention
Aspirin (50 to 150 mg) remains the cornerstone antithrombotic therapy, with an expected 13% relative risk reduction in serious vascular events. The addition of extended release dipyridamole (400 mg/d) to aspirin is expected to contribute a further 18% (9% to 26%) reduction in relative risk of serious vascular events. Clopidogrel appears to be marginally but significantly more effective that aspirin, based on the CAPRIE trial. The combination of aspirin and clopidogrel is not more effective than clopidogrel alone, but may be more effective than aspirin alone. As the latter observation is based on a posthoc subgroup analysis of CHARISMA, the combination of aspirin and clopidogrel is not usually indicated for long-term secondary prevention of recurrent vascular events among patients with TIA and ischemic stroke, unless there is another indication for use of the combination ie, recent acute coronary syndrome or percutaneous coronary intervention (particularly after insertion of a drug-eluting coronary stent). 69 Although indirect comparisons between trials of clopidogrel and combination aspirin/DPD suggest that aspirin/ DPD may be more effective for secondary prevention, the 2 regimens are being compared directly in the ongoing large PRoFESS trial, which should report its results in 2008 (Table 4) . 70 
Future Directions Present Antiplatelet Drugs
In the acute phase after ischemic stroke or TIA, a high priority is a dedicated evaluation, by means of an adequately powered clinical trial, of the safety and efficacy of adding clopidogrel, given as a loading dose of 300 or 600 mg, to aspirin in patients at high risk for early recurrent ischemic stroke (eg, with symptomatic large artery atherothromboembolism), and continued for a short period of about 3 months (during this time the benefits are likely to be greatest and the cumulative risks for bleeding lessened). Ongoing research also aims to identify the independent risk factors for bleeding complications associated with combination antiplatelet therapy, and the optimal antiplatelet regimens.
Novel Antiplatelet Drugs
At least 2 novel antiplatelet drugs are currently being evaluated for long-term management of patients with recent stroke or TIA.
The Prevention of cerebrovascular and cardiovascular Events of ischemic origin with terRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack (PERFORM) trial is underway and aims to randomize 18 000 patients with ischemic stroke or TIA of atherothrombotic origin to long-term treatment with aspirin or terutroban (S18886, a thromboxane receptor antagonist).
The Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TR 2P-TIMI 50) trial aims to randomize 19 500 high vascular risk patients with previous ischemic stroke, MI, or PAD (ABI Ͻ0.85 or prior revascularization or amputation) within the previous 2 weeks to 12 months to long-term treatment with aspirin 81 to 162 mg daily or SCH 530348 (a thrombin receptor antagonist) 2.5 mg per day.
Antiplatelet drugs that target the P2Y 12 receptor (eg, AZD-6140, prasugrel) are being evaluated as alternatives to clopidogrel or ticlopidine in patients with acute coronary syndromes or undergoing percutaneous coronary intervention but have not been evaluated in stroke. Other antiplatelet drugs that may have potential for the acute and long term management of stroke include thromboxane receptor antagonists (eg, S18886), combined thromboxane synthase/thromboxane receptor inhibitors, and drugs that selectively block the platelet ADP receptor P2Y 1 , glycoprotein Ib, Ia/IIa, and VI; HT2, and the thrombin (protease activated) receptor. Table 3 . Estimates of the absolute benefits and risks of antiplatelet drugs currently used for the management of stroke.
Disclosures
In the article entitled "Antiplatelet Therapy for Secondary Prevention of Noncardioembolic Ischemic Stroke: A Critical Review" by O'Donnell et al, 1 the authors report two errors. First, in Table 3 , under Cilostazol's Serious Vascular Event Risk Reduction (95% CI) column, the values should be "(0.41-0.91)" instead of "(0.41-0.01)." Second, on page 1641, the reference number of the "Efficacy" category under the "Cilostazol Versus Control" Section should be "41" instead of "42." The authors regret these errors.
The corrected version can be viewed online at http://stroke.ahajournals.org.
